Medical Device Veteran Mark J. Foley Named Chairman at Signum Surgical

Signum Surgical has appointed Mark J. Foley as board chairman. A highly accomplished medical device executive, Foley has decades of experience scaling innovative healthcare companies and driving sustained commercial success in the U.S. and international markets.

Foley joins Signum Surgical as it continues to expand the adoption and commercialization of its BioHealx technology, which has been on the U.S. market for the past nine months. Designed to treat anal fistulas; a debilitating and often recurring condition, BioHealx offers a minimally invasive solution addressing a significant unmet clinical need. Anal fistulas are estimated to affect one in 5,000 people worldwide.

“We are delighted to welcome Mark as chairman of the board at this pivotal stage of our expansion,” Signum Surgical President/CEO Carol A. Burns said. “His track record of building transformative technologies and scaling successful medical device companies will be instrumental as we grow our commercial footprint and bring BioHealx to more patients and physicians worldwide.”

The BioHealx Anal Fistula Device features a bioabsorbable helical implant with a mechanism of action that applies controlled extraluminal compression to close the fistula tract within the sphincter muscle. Clinical data demonstrate an 84.4% success rate, preservation of continence, and improved quality of life for patients. These outcomes position BioHealx as a compelling alternative to traditional surgical approaches, which can carry higher risks and variable results.

Foley has more than 30 years of experience in the global medical technology sector and has held senior leadership and board roles across multiple high-growth companies, including Zeltiq and Revance Therapeutics, where he helped guide strategic growth and successful outcomes.

“Signum Surgical is delivering an innovative solution for patients suffering from anal fistulas. With strong clinical outcomes, including high success rates and maintaining continence, BioHealx represents an important advancement in colorectal care,” Foley stated. “I am excited to join the company as it builds on its early commercial success and expands its reach.”

Signum Surgical is a commercial-stage medical technology company developing and delivering solutions for colorectal conditions. Its BioHealx platform is designed to provide effective, minimally invasive treatments that improve patient outcomes and quality of life.